Compare ENR & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ENR | REPL |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.3B |
| IPO Year | 2015 | 2018 |
| Metric | ENR | REPL |
|---|---|---|
| Price | $22.22 | $12.52 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 9 |
| Target Price | ★ $23.14 | $5.67 |
| AVG Volume (30 Days) | 833.9K | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-21-2026 |
| Dividend Yield | ★ 6.48% | N/A |
| EPS Growth | ★ 538.46 | N/A |
| EPS | ★ 3.32 | N/A |
| Revenue | ★ $2,952,700,000.00 | N/A |
| Revenue This Year | $3.87 | N/A |
| Revenue Next Year | $0.85 | N/A |
| P/E Ratio | $6.69 | ★ N/A |
| Revenue Growth | ★ 2.28 | N/A |
| 52 Week Low | $15.75 | $1.50 |
| 52 Week High | $26.14 | $16.33 |
| Indicator | ENR | REPL |
|---|---|---|
| Relative Strength Index (RSI) | 56.99 | 41.23 |
| Support Level | $19.47 | $12.40 |
| Resistance Level | $22.18 | $16.02 |
| Average True Range (ATR) | 0.70 | 0.73 |
| MACD | 0.17 | -0.22 |
| Stochastic Oscillator | 81.41 | 16.61 |
Energizer Holdings Inc. manufactures and distributes household batteries, specialty batteries, and lighting products. The company offers batteries using lithium, alkaline, carbon zinc, nickel metal hydride, zinc air, and silver oxide technologies, sold under the Energizer, Rayovac, Varta, and Eveready brands across performance and premium price segments. It also provides auto care products in the appearance, fragrance, performance, and air conditioning recharge categories. Energizer operates through two geographical segments, the United States and International, with the majority of its revenue generated in the United States. It has two product segments: Batteries and Lights and Auto Care, with the Batteries and Lights segment contributing the majority of its revenue.
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.